Clinical Trials

Access to Novel Treatments and Promising New Therapies

Research at Cancer Partners

We Are Committed to Innovation

Cancer Partners of Nebraska can now offer even more access to clinical trials, thanks to our membership in two major National Cancer Institute (NCI) research networks: Alliance as an affiliate of MD Anderson Cancer Center and ECOG-ACRIN Cancer Research Group.

  • Patient recruitment and enrollment in promising clinical trials is essential to the work that we do.
  • Cancer Partners is the first and only community oncology practice in Nebraska to become a member institution of the NCI clinical trials network.
  • The expanded clinical trials offered here bring academic-level treatment options to our local community.
  • We have access to over 300 new and innovative clinical trials for our patients.

Cancer Partners of Nebraska Human Research Protection Program

If you are not able to resolve your concerns with the study doctor or study staff, if you have a complaint, or if you have general questions about what it means to be in a research study, you can call the Cancer Partners of Nebraska Human Research Protection Program at (402) 420-7000, Ext. 202, or email HumanProtections@cancerpartners.com.

Clinical Trials

See What Clinical Trials Are Open Right Now

Most clinical trials at Cancer Partners are interventional studies, meaning patients are assigned to a treatment or other intervention and their outcomes are measured. See the full list below sorted by type of cancer. If you wish to discuss a specific trial, please discuss it with your oncologist or contact our Research Department at (402) 327-7363.

Breast Cancer

EA1181 – Her-2 positive Stage II-IIIa Breast Cancer

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Learn More

Central Nervous System Tumors (Brain and Spinal Cord) Cancer

A071702 - WHO Grade IV GBM (Glioblastoma)

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden

Learn More
NRG-BN007 (Glioblastoma)

TEMPORARILY CLOSED TO ACCRUAL – Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Learn More

Hematologic Cancer

CONNECT MDS/AML Myeloid Disorders

The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Learn More
INNOCARE ICP-CL-00107 (B-Cell Malignancies)

ONLY MCL ARM OPEN – A Phase I/II, Multicenter, Open-label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib. R/R MCL, MZL, FL or Dbl mutated DLBCL, and R/R or Treatment Naïve CLL/SLL

Learn More
S1918 (DLBCL age >75) Diffuse Large B Cell Lymphoma

A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements

Learn More
S1925 Asymptomatic High-Risk CLL/SLL

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed therapy with Venetoclax and Obinutzumab in Newly Diagnosed Asymptomatic High-Risk Patient with DLL/CLL: EVOLVE CLL/SLL Study.

Learn More
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with MM using minimal residual disease to direct therapy duration (DRAMMATIC STUDY).

Learn More

Gastrointestinal Cancer

A221805 – Stage II-III Colon Cancer Receiving Oxaliplatin (Early Stage Colon Cancer)

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Learn More
EA2186 GIANT - Metastatic Pancreatic

1ST line Metastatic Pancreatic – A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Learn More
KRYSTAL-10 Advanced Colorectal Cancer with IV KRAS G12C Mutation

Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Learn More

Thoracic Cancer

Unresectable Stage III or Metastatic (M1a) NSCLC - EF-36/Keynote B36

OPENING SOON – Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) (KEYNOTE B36)

Learn More
D9103C00001 – (PACIFIC-4) Non-Small Cell Lung Cancer (NSCLC) Patients

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-Small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Learn More
D910LC00001 (MeRmaiD-1) Operable Non-Small Cell Lung Cancer

Stage II-III Resected NSCLC – A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC

Learn More
A151216 - Resected Non-Small Cell Lung Cancer

Stage II-III Resected NSCLC – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Learn More
EA5182 - Stage IV EGFR Mutated NSCLC 1st line treatment (Metastatic Non-Small Cell lung cancer, EGRF Mutated)

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Learn More
A081801 - Stage II-III (Resected Non-Small Cell Lung Cancer)

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

Learn More
E4512 - Stage II-III ALK + Resected Non-Small Cell Lung Cancer

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Learn More
EA5181 - Unresectable Stage III Non-Small Cell Lung Cancer

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy of Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Learn More

Genitourinary Cancer

A031704 (PDIGREE) - Treatment Naïve Metastatic Renal Cell Carcinoma

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

Learn More
NRG-GU008 (INNOVATE) - Prostate Cancer, Treatment after Prostatectomy

Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy

Learn More
MK6482-011 - Progressive Metastatic Renal Cell Carcinoma

Phase 3 Study of MK-6482 in Combination With Lenvatinib Versus Cabozantinib for Second-line Treatment of mRCC

Learn More

Gynecological

NRG-GY023

A Randomized Phase II trial of triplet therapy (a PD-L1 inhibitor durvalumab in combination with Olaparib and Cediranib) compared to Olaparib and Cediranib or Durvalumab and Cediranib or standard of care chemotherapy in women with Platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal or fallopian cancer who have received prior Bevacizumab

Learn More

Solid Tumor

MK7339-002 (LYNK-002) Previously Treated, HRR/HRD +

A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Learn More

Cutaneous

CASE - Cutaneous Squamous Cell Carcinoma

Cemiplimab Survivorship Epidemiology Study

Learn More
S2000 - Metastatic Melanoma

A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases

Learn More

Survivorship

Biomarker

Caris Biorepository (Matched Tumor)

Solid Tumor Matched Tissue and Blood Collection

Learn More
MT Group (MTG-022)

The list of available biomarker studies is always changing. Please contact Cancer Partners Research Department for the most current list.

To Top